- Home
- TURN vs OTLK Comparison
TURN vs OTLK Comparison
Compare TURN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- OTLK
- Stock Information
- Founded
- TURN 1981
- OTLK 2010
- Country
- TURN United States
- OTLK United States
- Employees
- TURN N/A
- OTLK N/A
- Industry
- TURN Finance/Investors Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TURN Finance
- OTLK Health Care
- Exchange
- TURN Nasdaq
- OTLK Nasdaq
- Market Cap
- TURN 35.7M
- OTLK 35.0M
- IPO Year
- TURN N/A
- OTLK 2016
- Fundamental
- Price
- TURN $3.65
- OTLK $1.50
- Analyst Decision
- TURN
- OTLK Strong Buy
- Analyst Count
- TURN 0
- OTLK 7
- Target Price
- TURN N/A
- OTLK $40.57
- AVG Volume (30 Days)
- TURN 37.2K
- OTLK 4.6M
- Earning Date
- TURN 08-19-2024
- OTLK 02-12-2025
- Dividend Yield
- TURN N/A
- OTLK N/A
- EPS Growth
- TURN N/A
- OTLK N/A
- EPS
- TURN N/A
- OTLK N/A
- Revenue
- TURN $129,297.00
- OTLK N/A
- Revenue This Year
- TURN N/A
- OTLK N/A
- Revenue Next Year
- TURN N/A
- OTLK N/A
- P/E Ratio
- TURN N/A
- OTLK N/A
- Revenue Growth
- TURN 6.32
- OTLK N/A
- 52 Week Low
- TURN $3.12
- OTLK $0.87
- 52 Week High
- TURN $4.47
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- TURN 55.40
- OTLK 21.72
- Support Level
- TURN $3.61
- OTLK $1.35
- Resistance Level
- TURN $3.75
- OTLK $1.65
- Average True Range (ATR)
- TURN 0.11
- OTLK 0.22
- MACD
- TURN -0.01
- OTLK 0.03
- Stochastic Oscillator
- TURN 42.86
- OTLK 14.03
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.